Key Dates
February 12, 2026
Related Announcements
- December 14, 2022 - National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional). See NOFO PAR-23-059.
Issued by
National Cancer Institute (NCI)
Purpose
The purpose of this Notice is to extend the expiration date for PAR-23-059, National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional).
Therefore, with the addition/extension by one Application Due Date, PAR-23-059 now expires on September 8, 2026.
The following sections in Part 1. Overview Information, Key Dates section have been changed:
Currently reads:
| Application Due Dates | Review and Award Cycles | ||||
|---|---|---|---|---|---|
| New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| May 25, 2023 * | May 25, 2023 * | September 07, 2023 * | November 2023 | January 2024 | April 2024 |
| September 25, 2023 * | September 25, 2023 * | January 07, 2024 * | March 2024 | May 2024 | July 2024 |
| January 25, 2024 * | January 25, 2024 * | May 07, 2024 * | July 2024 | October 2024 | December 2024 |
| May 25, 2024 * | May 25, 2024 * | September 07, 2024 * | November 2024 | January 2025 | April 2025 |
| September 25, 2024 * | September 25, 2024 * | January 07, 2025 * | March 2025 | May 2025 | July 2025 |
| January 25, 2025 * | January 25, 2025 * | May 07, 2025 * | July 2025 | October 2025 | December 2025 |
| May 25, 2025 * | May 25, 2025 * | September 07, 2025 * | November 2025 | January 2026 | April 2026 |
| September 25, 2025 * | September 25, 2025 * | January 07, 2026 * | March 2026 | May 2026 | July 2026 |
| January 25, 2026 * | January 25, 2026 * | May 07, 2026 * | July 2026 | October 2026 | December 2026 |
Expiration Date: May 08, 2026
Modified to read (in bold italics):
Application Due Dates | Review and Award Cycles | |||
|---|---|---|---|---|
| New | Renewal / Resubmission / Revision (as allowed) | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| May 25, 2023 * | May 25, 2023 * | November 2023 | January 2024 | April 2024 |
| September 25, 2023 * | September 25, 2023 * | March 2024 | May 2024 | July 2024 |
| January 25, 2024 * | January 25, 2024 * | July 2024 | October 2024 | December 2024 |
| May 25, 2024 * | May 25, 2024 * | November 2024 | January 2025 | April 2025 |
| September 25, 2024 * | September 25, 2024 * | March 2025 | May 2025 | July 2025 |
| January 25, 2025 * | January 25, 2025 * | July 2025 | October 2025 | December 2025 |
| May 25, 2025 * | May 25, 2025 * | November 2025 | January 2026 | April 2026 |
| September 25, 2025 * | September 25, 2025 * | March 2026 | May 2026 | July 2026 |
| January 25, 2026 * | January 25, 2026 * | July 2026 | October 2026 | December 2026 |
| May 25, 2026 * | May 25, 2026 * | November 2026 | January 2027 | April 2027 |
Expiration Date: May 26, 2026
All other aspects of PAR-23-059 remain unchanged.
Inquiries
Please direct all inquiries to:
Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: [email protected]
and Human Services (HHS)
